Physician profile
Beth A Buscher
NPI 1427053776
$10,952.57
in general payments reported to CMS, 2019-2025
35 companies · $1,401 in 2025
The $1,401 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,605 · 2020: $731 · 2021: $1,127 · 2022: $1,895 · 2023: $1,733 · 2024: $1,461 · 2025: $1,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,564 · Education: $30.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,564.14 |
| Education | $30.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,069.85 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Allergan, INC. | $1,881.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $842.41 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $834.38 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Janssen Biotech, INC. | $718.52 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $689.00 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Leo Pharma INC. | $587.21 | 2019-2025 | Adbry |
| Pfizer INC. | $432.90 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $429.90 | 2019-2024 | Odomzo, Blu-U, Winlevi |
| Ucb, INC. | $306.01 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $297.78 | 2019-2023 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $275.63 | 2023-2025 | Sotyktu |
| Incyte Corporation | $178.46 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $155.18 | 2021-2023 | Olumiant, Taltz |
| Almirall LLC | $144.42 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $137.84 | 2022 | |
| Amgen INC. | $129.37 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $116.55 | 2023-2025 | Zoryve |
| Genzyme Corporation | $108.23 | 2019-2025 | |
| Journey Medical Corporation | $96.05 | 2019-2024 | |
| Epi Health, LLC | $89.34 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $77.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.95 | 2024-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $51.52 | 2020 | |
| Genentech USA, INC. | $47.15 | 2020-2022 | |
| Organon LLC | $36.63 | 2025 | Vtama |
| Biofrontera INC. | $30.30 | 2022 | |
| Dusa Pharmaceuticals, INC. | $24.08 | 2019 | |
| Dermavant Sciences, INC. | $20.17 | 2024 | Vtama |
| Solta Medical, A Division of Bausch Health US, LLC | $19.26 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.82 | 2022 | |
| Merck Sharp & Dohme LLC | $15.78 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $15.16 | 2019 | |
| Medtronic Vascular, INC. | $14.41 | 2019 | |
| Mayne Pharma Commercial LLC | $9.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Buscher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.